NASDAQ:PRAH - PRA Health Sciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$114.13 +2.14 (+1.91 %)
(As of 02/22/2019 04:00 PM ET)
Previous Close$114.13
Today's Range$112.03 - $114.2950
52-Week Range$79.20 - $121.98
Volume288,103 shs
Average Volume319,586 shs
Market Capitalization$7.42 billion
P/E Ratio35.67
Dividend YieldN/A
Beta1.14
PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, and bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include targeting and compensation services, and pharmaceutical audit suite; brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services. The company conducts clinical trials in the areas of pharmaceutical development, including oncology, central nervous system, inflammation, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.

Receive PRAH News and Ratings via Email

Sign-up to receive the latest news and ratings for PRAH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRAH
CUSIPN/A
Phone919-786-8200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.26 billion
Cash Flow$4.7853 per share
Book Value$14.78 per share

Profitability

Net Income$86.92 million

Miscellaneous

Employees15,800
Market Cap$7.42 billion
Next Earnings Date2/27/2019 (Confirmed)
OptionableOptionable

PRA Health Sciences (NASDAQ:PRAH) Frequently Asked Questions

What is PRA Health Sciences' stock symbol?

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

How were PRA Health Sciences' earnings last quarter?

PRA Health Sciences Inc (NASDAQ:PRAH) released its earnings results on Wednesday, October, 31st. The medical research company reported $1.13 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.07 by $0.06. The medical research company earned $717.60 million during the quarter, compared to the consensus estimate of $729.63 million. PRA Health Sciences had a return on equity of 25.75% and a net margin of 2.37%. The business's revenue for the quarter was up 23.3% on a year-over-year basis. During the same period last year, the business posted $0.88 earnings per share. View PRA Health Sciences' Earnings History.

When is PRA Health Sciences' next earnings date?

PRA Health Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for PRA Health Sciences.

What price target have analysts set for PRAH?

8 Wall Street analysts have issued 12-month target prices for PRA Health Sciences' stock. Their predictions range from $100.00 to $120.00. On average, they anticipate PRA Health Sciences' stock price to reach $113.50 in the next year. This suggests that the stock has a possible downside of 0.6%. View Analyst Price Targets for PRA Health Sciences.

What is the consensus analysts' recommendation for PRA Health Sciences?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PRA Health Sciences.

Has PRA Health Sciences been receiving favorable news coverage?

Press coverage about PRAH stock has trended somewhat positive this week, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. PRA Health Sciences earned a daily sentiment score of 1.7 on InfoTrie's scale. They also gave media coverage about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future.

Who are some of PRA Health Sciences' key competitors?

What other stocks do shareholders of PRA Health Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PRA Health Sciences investors own include Alibaba Group (BABA), NVIDIA (NVDA), General Electric (GE), Twitter (TWTR), Mattel (MAT), Ultra Clean (UCTT), Paypal (PYPL), Adobe (ADBE), salesforce.com (CRM) and Chevron (CVX).

Who are PRA Health Sciences' key executives?

PRA Health Sciences' management team includes the folowing people:
  • Mr. Colin Shannon, Chairman, CEO & Pres (Age 60)
  • Mr. Michael J. Bonello, Exec. VP & CFO
  • Christine Rogers, Director of PR & Corp. Communications
  • Mr. Patrick R. Spine, VP of HR
  • Mr. Pedro Vinals, VP of Operations & GP

When did PRA Health Sciences IPO?

(PRAH) raised $306 million in an initial public offering on Thursday, November 13th 2014. The company issued 17,000,000 shares at a price of $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

Who are PRA Health Sciences' major shareholders?

PRA Health Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.48%), Bank of New York Mellon Corp (3.37%), Eagle Asset Management Inc. (1.64%), Pendal Group Ltd (1.36%), Frontier Capital Management Co. LLC (1.34%) and Jennison Associates LLC (1.33%). Company insiders that own PRA Health Sciences stock include Colin Shannon, David W Dockhorn, Linda Baddour, Matthew P Young and Pra Investors LP Kkr. View Institutional Ownership Trends for PRA Health Sciences.

Which institutional investors are selling PRA Health Sciences stock?

PRAH stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Acadian Asset Management LLC, Swedbank, Bank of America Corp DE, Los Angeles Capital Management & Equity Research Inc., Vaughan Nelson Investment Management L.P., Gotham Asset Management LLC and Mitchell Capital Management Co.. View Insider Buying and Selling for PRA Health Sciences.

Which institutional investors are buying PRA Health Sciences stock?

PRAH stock was bought by a variety of institutional investors in the last quarter, including Pendal Group Ltd, Standard Life Aberdeen plc, Millennium Management LLC, Prudential Financial Inc., First Trust Advisors LP, Frontier Capital Management Co. LLC, Assenagon Asset Management S.A. and Mackay Shields LLC. View Insider Buying and Selling for PRA Health Sciences.

How do I buy shares of PRA Health Sciences?

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PRA Health Sciences' stock price today?

One share of PRAH stock can currently be purchased for approximately $114.13.

How big of a company is PRA Health Sciences?

PRA Health Sciences has a market capitalization of $7.42 billion and generates $2.26 billion in revenue each year. The medical research company earns $86.92 million in net income (profit) each year or $3.20 on an earnings per share basis. PRA Health Sciences employs 15,800 workers across the globe.

What is PRA Health Sciences' official website?

The official website for PRA Health Sciences is http://www.prahs.com.

How can I contact PRA Health Sciences?

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]


MarketBeat Community Rating for PRA Health Sciences (NASDAQ PRAH)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  284 (Vote Outperform)
Underperform Votes:  242 (Vote Underperform)
Total Votes:  526
MarketBeat's community ratings are surveys of what our community members think about PRA Health Sciences and other stocks. Vote "Outperform" if you believe PRAH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRAH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2019 by MarketBeat.com Staff

Featured Article: Cost of Capital Explained

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel